Breast Cancer section

Breast Cancer News & Features

PAM50 HER2-E Subtype Predicts pCR Following Lapatinib, Trastuzumab

PAM50 HER2-E Subtype Predicts pCR Following Lapatinib, Trastuzumab

In this presentation at SABCS 2016, researchers present an evaluation of the ability of the PAM50 HER2-enriched intrinsic subtype to predict pathologic complete response in the breast in patients who received 18 weeks of neoadjuvant dual HER2 blockade.

Arsenic Pretreatment May Protect Normal Tissue During Chemo in Breast Cancer

Arsenic Pretreatment May Protect Normal Tissue During Chemo in Breast Cancer

Researchers found that temporary pretreatment with LDA may protect normal breast tissue during chemotherapy for breast cancer in patients undergoing breast-conserving therapy, according to a study presented at SABCS 2016.

Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC

Netupitant/Palonosetron Efficacious for Prevention of N/V in Patients Receiving MEC or HEC

In a poster presentation at SABCS 2016, researchers reported on the efficacy and safety of netupitant/palonosetron (NEPA) for the prevention of CINV in patients receiving highly or moderately emetogenic chemotherapy.

Costs, Complications Higher for Women Who Undergo Second Surgery After BCS

Costs, Complications Higher for Women Who Undergo Second Surgery After BCS

A study presented at SABCS 2016 reports on the incidence of complications and costs in women who undergo breast-conserving surgery for breast carcinoma.

Omitting RT in Certain Older Women With Early Breast Cancer is Safe

Omitting RT in Certain Older Women With Early Breast Cancer is Safe

Researchers report their study findings on the safety of omitting radiotherapy after breast-conserving surgery, sentinel node biopsy, and adjuvant endocrine therapy in older patients with early breast cancer and favorable histopathology at SABCS 2016.

Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression

Fluorescent Nanoparticles Represent Novel Detection Method of HER2 Expression

Researchers investigated the potential of PID fluorescent nanoparticles, a novel detection technique to visualize and quantify protein in clinical samples, for quantifying HER2 protein expression in breast cancer, according to a study presented at SABCS 2016.

Assessment of Stromal Features in DCIS Requires Robustness

Assessment of Stromal Features in DCIS Requires Robustness

Robustness of dichotomous assessment is important when evaluating stromal features of ductal carcinoma in situ (DCIS), according to a study presented at SABCS 2016.

RANKL Inhibition May Represent Promising Breast Cancer Prevention Strategy

RANKL Inhibition May Represent Promising Breast Cancer Prevention Strategy

Research presented at 2016 SABCS showed whether RANKL inhibition could reduce the risk for developing breast cancer in BRCA1 mutation carriers.

Bi-allelic Inactivation Common in BRCA1 and BRCA Breast Cancers

Bi-allelic Inactivation Common in BRCA1 and BRCA Breast Cancers

Bi-allelic inactivation of BRCA1 and BRCA2 are frequent events in BRCA1 breast cancers and BRCA2 breast cancers, respectively, according to a study presented at SABCS 2016.

In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS

In HER2+ Breast Cancer, Higher TIL Levels Associated With Improved OS

In this study presented at SABCS 2016, investigators determined the association between higher TIL levels and overall survival in patients with advanced HER2-positive breast cancer treated with docetaxel plus trastuzumab in combination with pertuzumab or placebo.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs